A prospective study of an alemtuzumab containing reduced-intensity allogeneic stem cell transplant program in patients with poor-risk and advanced lymphoid malignancies Journal Article

   


Authors: Sauter, C. S.; Chou, J. F.; Papadopoulos, E. B.; Perales, M. A.; Jakubowski, A. A.; Young, J. W.; Scordo, M.; Giralt, S.; Castro-Malaspina, H.
Article Title: A prospective study of an alemtuzumab containing reduced-intensity allogeneic stem cell transplant program in patients with poor-risk and advanced lymphoid malignancies
Abstract: Reduced-intensity conditioning (RIC) regimens for allogeneic stem cell transplant (allo-SCT) have used alemtuzumab to abrogate the risk of graft-versus-host disease (GVHD). Thirty-eight patients with advanced lymphoma underwent a prospective phase II study of melphalan, fludarabine and alemtuzumab containing RIC allo-SCT from 20 matched related and 18 unrelated donors with cyclosporine-A as GVHD prophylaxis. The cumulative incidence of grade II-IV acute GVHD at 3 months was 10.5% and three evaluable patients experienced chronic GVHD. Progression-free (PFS) and overall (OS) survival at 5 years was 25% (95% confidence interval [CI]: 13-40%) and 44% (95% CI: 28-59%), respectively. Previous high-dose therapy and autologous stem cell transplant (HDT-ASCT) and elevated lactate dehydrogenase (LDH) at the time of allo-SCT resulted in inferior OS. Within this cohort of patients with high-risk lymphoma, alemtuzumab containing RIC resulted in a low risk of GVHD and a high incidence of progression of disease, especially in those with poor-risk features defined by elevated LDH pre-allo-SCT and previous HDT-ASCT.
Keywords: lymphoma; alemtuzumab; allogeneic transplant; reduced-intensity
Journal Title: Leukemia and Lymphoma
Volume: 55
Issue: 12
ISSN: 1042-8194
Publisher: Taylor & Francis Group  
Date Published: 2014-12-01
Start Page: 2739
End Page: 2747
Language: English
DOI: 10.3109/10428194.2014.894185
PROVIDER: scopus
PUBMED: 24528216
PMCID: PMC4372088
DOI/URL:

http://www.scopus.com/inward/record.url?eid=2-s2.0-84919428945&partnerID=40&md5=dfaeae44576f6f9ad3c4c71abaae2f9f
Notes: Export Date: 2 January 2015 -- Source: Scopus
Altmetric
What is Altmetric?
Citation Impact
What is Dimensions Citation Badge?
MSK Authors
  1. Joanne Fu-Lou Chou
    299 Chou
  2. Sergio Andres Giralt
    993 Giralt
  3. Craig Steven Sauter
    333 Sauter
  4. Esperanza B Papadopoulos
    407 Papadopoulos
  5. Ann Jakubowski
    449 Jakubowski
  6. Miguel-Angel Perales
    840 Perales
  7. James W Young
    317 Young
  8. Hugo Castro-Malaspina
    332 Castro-Malaspina
Related MSK Work